SPA Pricing Education, Analytics & Decision Making Tools Webinar Series

Tag: Drug Pricing

New price for muscular dystrophy drug draws criticism | CNBC

New price for muscular dystrophy drug draws criticism | CNBC

Deflazacort wasn’t approved in the U.S., so McSherry and a number of other families of kids with Duchenne imported the drug from overseas. She says it cost about $1,200 a year out of pocket. Monday, deflazacort got a new price tag: $35,000 a year for a patient in the U.S. weighing 25 kilograms, or about […]

Big Pharma Losing Leverage as Payers Raise Pressure on Price | Bloomberg

Big Pharma Losing Leverage as Payers Raise Pressure on Price | Bloomberg

The world’s biggest drugmakers don’t have the muscle they used to have. Pharmaceutical and biotechnology giants are finding it more difficult to charge high prices for a range of medications, their latest quarterly results show. That’s raising the pressure to pump up sales volumes and find lucrative new treatments for niche markets. “You had an […]

Fair pricing or pricing for profit? | CMAJ News

Fair pricing or pricing for profit? | CMAJ News

If you had $500 000, would you provide drugs to one person who has a rare disease for a year, cure ten people of hepatitis C, or treat 500 with diabetes? This sort of question is plaguing cash-strapped public pharmacare programs in Canada. What is fair pricing? It’s a question making headlines and prompting debate, such […]

Two states probe Eli Lilly over high insulin pricing | Axios

Two states probe Eli Lilly over high insulin pricing | Axios

Pharmaceutical giant Eli Lilly is facing civil investigations from attorneys general in New Mexico and Washington into its insulin prices, according to Lilly’s latest quarterly filing. Washington’s attorney general is also looking into Lilly’s relationships with pharmacy benefit mangers — the middlemen who negotiate drug prices for insurance companies and employers. Read complete article here: […]

Amgen: The Bear Case From a Bull | Madison.com

Amgen: The Bear Case From a Bull | Madison.com

Long story short, the recent introduction of Inflectra, Pfizer’s (NYSE: PFE) biosimilar to Johnson & Johnson’s (NYSE: JNJ) Remicade, could negatively affect the pricing power for anti-inflammatory drugs as a whole. After all, Pfizer has already announced that Inflectra will initially be sold at a 15% discount to the wholesaler acquisition cost of J&J’s Remicade, which may spur a round of deeper […]

Better Buy: Amgen Inc. vs. Biogen | The Motley Fool

Better Buy: Amgen Inc. vs. Biogen | The Motley Fool

Valeant Pharmaceuticals (NYSE:VRX) has been more bullish about the prospects for brodalumab, now branded as Siliq, than anyone. Amgen bailed out on the psoriasis drug after late-stage study results raised concerns about Siliq causing patients to have suicidal thoughts. AstraZeneca publicly stated that it would move forward without Amgen, but soon afterward began shopping the drug […]

Marathon Pharmaceutical resigns from industry lobbying group PhRMA following pricing controversy | Healthcare Finance

Marathon Pharmaceutical resigns from industry lobbying group PhRMA following pricing controversy | Healthcare Finance

With the sale of its controversial rare-disease drug finalized, Marathon Pharmaceuticals has taken the unusual step of resigning from the powerful industry lobbying group PhRMA.| Marathon had been a member of the Pharmaceutical Research and Manufacturers of America, and Marathon’s CEO, Jeffrey Aronin, had held a position on the board. The news of Marathon’s resignation […]

EU regulators back two more orphan drugs, question of pricing remains | Pharmaphorum

EU regulators back two more orphan drugs, question of pricing remains | Pharmaphorum

Approved in the US late last year, Biogen charges $750,000 for six jabs of Spinraza (nusinersen) in the first year of treatment – although the price halves from the second year onwards as only three doses are required annually. It’s unclear what Biogen’s pricing strategy will be in Europe, where the firm will have to […]

BioMarin sees ‘high end’ pricing on Brineura ahead of FDA decision: analyst | FiercePharma

BioMarin sees ‘high end’ pricing on Brineura ahead of FDA decision: analyst | FiercePharma

But BioMarin is warning that the med will be near the top of the world’s costliest orphan drugs, and that growth will be slow because it treats an “extremely rare” disease, according to Schimmer. In an effort to boost the drug’s prospects, BioMarin plans to search “ aggressively” for early-stage and minimally symptomatic patients, the analyst […]

U.S. Army Rejects Pricing Concerns in Grant of Exclusive Patent License to Sanofi on Zika Vaccine | Knowledge Ecology International

U.S. Army Rejects Pricing Concerns in Grant of Exclusive Patent License to Sanofi on Zika Vaccine | Knowledge Ecology International

On December 21, 2016, KEI asked the Army to include reasonable pricing terms in the exclusive license, in order to ensure an affordable price on the vaccine for U.S. taxpayers and people in low income countries. On January 12, 2017, KEI, the American Federation of State, County and Municipal Employees (AFSCME), People of Faith for […]